Jeil Pharm (002620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.031x

Based on the latest financial reports, Jeil Pharm (002620) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.16 Billion ≈ $9.60 Million USD) by net assets (₩460.63 Billion ≈ $312.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Jeil Pharm - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Jeil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jeil Pharm debt and liabilities for a breakdown of total debt and financial obligations.

Jeil Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jeil Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Fluent Inc NASDAQ:FLNT	-0.350x
Gowa Makassar Tourism Develop JK:GMTD	-0.016x
Austral Resources Australia Ltd AU:AR1	-0.065x
Bon Fame Co Ltd TWO:8433	0.021x
Parkit Enterprise Inc V:PKT	0.019x
Digital Mediatama Maxima PT JK:DMMX	-0.035x
Avgol Industries 1953 Ltd TA:AVGL	0.038x
Dogusan Boru Sanayi ve Ticaret AS IS:DOGUB	-0.014x

Annual Cash Flow Conversion Efficiency for Jeil Pharm (2011–2024)

The table below shows the annual cash flow conversion efficiency of Jeil Pharm from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Jeil Pharm market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩437.40 Billion ≈ $296.42 Million	₩4.54 Billion ≈ $3.08 Million	0.010x	+194.59%
2023-12-31	₩402.19 Billion ≈ $272.56 Million	₩-4.42 Billion ≈ $-2.99 Million	-0.011x	+77.84%
2022-12-31	₩419.79 Billion ≈ $284.49 Million	₩-20.80 Billion ≈ $-14.10 Million	-0.050x	-284.97%
2021-12-31	₩500.31 Billion ≈ $339.06 Million	₩13.40 Billion ≈ $9.08 Million	0.027x	+156.50%
2020-12-31	₩499.28 Billion ≈ $338.36 Million	₩-23.67 Billion ≈ $-16.04 Million	-0.047x	-190.82%
2019-12-31	₩483.04 Billion ≈ $327.35 Million	₩25.22 Billion ≈ $17.09 Million	0.052x	+996.58%
2018-12-31	₩589.58 Billion ≈ $399.55 Million	₩-3.43 Billion ≈ $-2.33 Million	-0.006x	-116.75%
2017-12-31	₩170.44 Billion ≈ $115.50 Million	₩5.92 Billion ≈ $4.01 Million	0.035x	-22.85%
2016-12-31	₩252.08 Billion ≈ $170.83 Million	₩11.36 Billion ≈ $7.70 Million	0.045x	+296.38%
2015-12-31	₩241.39 Billion ≈ $163.59 Million	₩2.74 Billion ≈ $1.86 Million	0.011x	+169.58%
2012-12-31	₩241.41 Billion ≈ $163.60 Million	₩-3.94 Billion ≈ $-2.67 Million	-0.016x	-116.00%
2011-12-31	₩231.40 Billion ≈ $156.81 Million	₩23.63 Billion ≈ $16.01 Million	0.102x	--

About Jeil Pharm

KO:002620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$93.63 Million

₩138.16 Billion KRW

Market Cap Rank

#19427 Global

#1071 in Korea

Share Price

₩9000.00

Change (1 day)

-1.10%

52-Week Range

₩7530.00 - ₩9280.00

All Time High

₩92178.44